Trial Profile
Efficacy and Security of Bezafibrate in Patients With Primary Biliary Cirrhosis Without Biochemical Response to Ursodeoxycholic Acid: A Randomized, Double-blind, Placebo-controlled Trial
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Bezafibrate (Primary) ; Ursodeoxycholic acid
- Indications Primary biliary cirrhosis
- Focus Therapeutic Use
- 25 Apr 2018 New trial record